Objectives To develop and evaluate a procedure for quantifying the hepatocyte-specific uptake of Gd-BOPTA and Gd-EOB-DTPA using dynamic contrast-enhanced (DCE) MRI. Methods Ten healthy volunteers were prospectively recruited and 21 patients with suspected hepatobiliary disease were retrospectively evaluated. All subjects were examined with DCE-MRI using 0.025 mmol/kg of Gd-EOB-DTPA. The healthy volunteers underwent an additional examination using 0.05 mmol/kg of Gd-BOPTA. The signal intensities (SI) of liver and spleen parenchyma were obtained from unenhanced and enhanced acquisitions. Using pharmacokinetic models of the liver and spleen, and an SI rescaling procedure, a hepatic uptake rate, K Hep , estimate was derived. The K Hep values for Gd-EOB-DTPA were then studied in relation to those for Gd-BOPTA and to a clinical classification of the patient's hepatobiliary dysfunction. Results K Hep estimated using Gd-EOB-DTPA showed a significant Pearson correlation with K Hep estimated using Gd-BOPTA (r=0.64; P<0.05) in healthy subjects. Patients with impaired hepatobiliary function had significantly lower K Hep than patients with normal hepatobiliary function (K Hep =0.09±0.05 min -1 versus K Hep =0.24±0.10 min −1 ;
Introduction
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) methods with both gadoxetate (Gd-EOB-DTPA; Primovist ® Bayer Schering Pharma, Berlin, Germany) and gadobenate dimeglumine (Gd-BOPTA; MultiHance ® Bracco Imaging, Milan, Italy) have been proposed as promising methods for the characterisation of liver function and staging of liver fibrosis [1, 2] . There is a major pharmacokinetic difference regarding the elimination of the two contrast agents: Gd-EOB-DTPA has a higher hepatobiliary excretion, 50%, compared with 2-4% for Gd-BOPTA [3] .
Based on investigations in a rat model, Tsuda et al. have shown that characterisation of both the early and the late uptake of Gd-EOB-DTPA enables separation of rats with non-alcoholic fatty liver disease (NAFLD) from rats with non-alcoholic steatohepatitis (NASH) [4] . In another study by Planchamp et al., a relationship between the pharmacokinetic parameters of Gd-BOPTA uptake in rat liver was shown to correlate negatively with the degree of liver fibrosis [5] . Recently, a retrospective study on patients by Motosugi et al. described a relationship between liver signal intensity (SI) in the late phases after Gd-EOB-DTPA injection and liver function measured with indocyanine green (ICG) clearance and Child-Pugh class [6] .
The transfer of analysis methods developed in rat models to studies in humans is difficult, as the pharmacokinetics of Gd-EOB-DTPA and Gd-BOPTA are slower in humans. The complete time course of the accumulation and excretion of contrast agents is too long to be observed in a standard clinical setting. Still, it is feasible to analyse the contrast agent accumulation in the hepatobiliary phase, as has been described by Motosugi et al. and Yamada et al. , who used a semi-quantitative approach relating the liver SI to the splenic SI [7, 8] .
An important problem in contrast-enhanced MRI is the fact that SI is defined on an arbitrary scale which can neither be compared between repeated examinations of the same patient, nor between different patients. Differences in radiofrequency (RF) coil loading, B 1 -field heterogeneity, repetition times (T R ), longitudinal relaxation time (T 1 ), transverse relaxation time (T 2 or T 2 * ) and patient/respiratory motion all influence the observed SI [9] . Although techniques exist that are capable of producing quantitative images of the T 1 relaxation [10] , a number of critical image quality parameters, such as spatial or temporal resolution, volume coverage and compensation for patient motion, are sub-optimal for a satisfactory clinical characterisation of focal lesions. However, by careful analysis of the signal intensities in T 1 -weighted gradient echo (GRE) imaging, it is possible to calculate a time series of sufficiently accurate relaxation rate values that are intrinsically proportional to contrast agent concentration, although the possible influence of disease-or treatment-induced alterations in native tissue T 1 should be considered [11] . Such quantitatively derived estimates are useful and even necessary for reproducible and robust evaluation of function and morphology, which could be applied in, for example, preoperative liver function evaluation for planning of segmental liver resections or in treatment evaluation.
The aim of the present work was to develop a procedure for quantifying the hepatocyte-specific contrast agent uptake during late time phases using standard imaging protocols. This procedure was evaluated in healthy volunteers using both Gd-EOB-DTPA and Gd-BOPTA, to investigate whether the uptake of Gd-BOPTA correlated with the hepatic uptake of Gd-EOB-DTPA. The hepatocytespecific uptake was also evaluated in patients to investigate whether impaired hepatobiliary function influences the hepatic uptake of Gd-EOB-DTPA.
Materials and methods

Subjects
The study comprised two different categories of subjects: healthy volunteers examined using both Gd-EOB-DTPA and Gd-BOPTA, and patients examined using only Gd-EOB-DTPA.
The healthy volunteer group consisted of five women (mean age: 25 years, range: 22-33 years) and five men (mean age: 25 years, range: 23-27 years). The patient group, including all patients who had been examined with For all patients, serum bilirubin, and other laboratory tests were retrieved to calculate the Child-Pugh [12] and model for end-stage liver disease (MELD) [13] scores.
The clinical grading of the hepatobiliary function of every patient at the time of the MRI examination, using the electronic patient records but without knowledge of MRI analyses, was performed retrospectively by a liver surgeon in three separate groups according to Table 1 . The study protocol was approved by the regional ethics committees in Stockholm and Linköping (Sweden).
Contrast agents
All healthy volunteers were examined on two occasions at least 3 weeks apart using two different liver-specific contrast agents, 0.025 mmol/kg of Gd-EOB-DTPA (Primovist ® 0.25 mmol/ml, Bayer Schering Pharma, Berlin, Germany) and 0.05 mmol/kg of Gd-BOPTA (MultiHance ® 0.5 mmol/ml; Bracco Imaging, Milan, Italy). The bolus was injected manually at 1 mL/s, immediately followed by an equal amount of saline. The arterial phase data acquisition was started 15-20 s post-injection, and the venous phase started approximately 60 s post-injection.
The patients were examined in accordance with our standard clinical liver MRI protocol. 0.025 mmol/kg of Gd-EOB-DTPA was administered intravenously at a rate of 1 mL/s using a power injector (Medrad Spectris Solaris, Pittsburgh, PA, USA), and immediately followed by an equal amount of saline. The timing of the arterial phase was determined by real-time bolus monitoring at the level of the upper abdominal aorta. Delayed acquisitions of the hepatobiliary phase were obtained in both groups, as specified in Table 2 .
Data acquisition
All examinations were performed on a 1.5 T magnetic resonance system (Achieva, Philips Medical Systems, Best, The Netherlands), using a phased-array body coil. The examinations were performed after at least 7 h of fasting. The study protocol to examine the healthy subjects contained one unenhanced and six enhanced acquisitions of an axial single breath-hold, fat-saturated, T 1 -weighted, 3D GRE sequence. The clinical protocol contained a total of five enhanced acquisitions. Pulse sequence details are given in Table 2 .
Image analysis
Signal intensity curves were obtained using the averages from seven regions of interest (ROIs) located in the liver and three ROIs in the spleen. The liver ROIs were distributed in both the left and right lobes, and placed in parenchymal areas without any large vessels, or focal lesions (Fig. 1) . Particular care was taken to preserve the correct scaling of the signal in the original images to enable the analysis and comparison of signal measurements from different images in the time series.
Normalisation of SI
The SI time series [SI(t)] from each individual ROI was then normalised by dividing it by the unenhanced signal intensity [SI(0)]. The signal normalisation removed constant background effects on the SI that occurred throughout the time series resulting from differences in image sensitivity, proton density, transverse relaxation and fatty infiltration. Thus, the normalised signal intensity, S, is given by:
Conversion of SI values to relaxation rate The normalised SI values were then recalculated to relaxation rate values, assuming fixed unenhanced or intrinsic T 1 values, T 10 =T 1 (0). These were 586 ms for the liver and 1057 ms for the spleen ROIs [14] . Correction was also made for non-linear effects from the chosen T R , and the flip angle (α) in this procedure. The signal intensity in a gradient echo sequence [15] follows approximately, where ξ is a constant describing the sensitivity of the MRI, and E(t) is equal to
Then,
Re-arrangement of this equation leads to the following non-linear expression for R1ðtÞ ¼ 1=T 1 ðtÞ:
A step-by-step illustration of the process is provided in Fig. 2 , where the effects of different intrinsic T 1 and of noise are also demonstrated.
There are two important reasons to incorporate such correction procedures in the analysis of signal intensities in quantitative dynamic contrast-enhanced studies. First, the slope in the SI response to contrast medium concentration is a function of the intrinsic tissue T 1 before injection of a contrast agent. Second, there is also a non-linear response of the SI for T 1 values that are short in relation to T R and α.
Calculation of contrast agent concentration
After recalculation of the SI to R 1 values, a linear relation [16] that depends on the contrast agent concentration (C) in the tissue was assumed as follows: where r 1 is the relaxivity of the contrast agent in situ in the tissue and ΔR 1 the induced increase in the relaxation rate. The assumed linear relationship between contrast agent concentration in the tissue and ΔR 1 allowed us to calculate a 'dose normalised' ΔR 1 by multiplying by 1/2 the estimated ΔR 1 in the examinations of healthy volunteers using Gd-BOPTA, as the injected dose of Gd-BOPTA was twice the injected dose of Gd-EOB-DTPA.
Pharmacokinetic analysis
The pharmacokinetic analysis of the time series was based on a two-compartment model of the liver and spleen (Fig. 3) . The splenic tissue was represented by one compartment consisting of splenic blood and extracellular extravascular space (EES) which was exposed to the blood contrast agent concentration, and one intracellular compartment that was inaccessible to the . b After application of Eq. 4 the increase in normalised SI was recalculated to an increase in R 1 values. The yellow area indicates the R 1 increase observed in this study. c The effect of unenhanced T 10 values deviating from the expected by ± one standard deviation (SD) observed in healthy individuals by de Bazelaire et al. [14] (39 ms for liver and 42 ms for spleen). d The sensitivity of the R 1 recalculation to noise was investigated by adding Gaussian noise (10% of the unenhanced SI) to the normalised SI values contrast agent. The liver tissue was similarly described using one blood and EES compartment exposed to the blood contrast agent concentration and one hepatobiliary compartment, accessible to the contrast agent via its transport over the basolateral membrane of the hepatocytes. The model did not distinguish between hepatocytic intracellular contrast agent and contrast agent transported into the biliary ductules.
The volume fractions of the combined blood and EES compartments to the total tissue water content in the liver (8 Liver ) and spleen (8 Spleen ) were used to adjust for the different signal contributions from the different compartments. In this model the total increase in R 1 in the liver (ΔR 1Liver ) is given by
The corresponding R 1 increase in the spleen (ΔR 1Spleen ), assuming no contribution from the intracellular splenic compartment, was related to the R 1 increase in the blood and EES compartment (ΔR 1Blood&EES ) via the following relation
From these equations, the increase in hepatobiliary R 1 (ΔR 1Hepatobiliary ) was defined as follows:
The conversion of ΔR 1Hepatobiliary to contrast agent concentration was not straightforward because of uncertainty regarding the exact values of 8 Liver and 8 Spleen , and the tissue-specific relaxivity in hepatocytes and bile. Furthermore, the comparison of ΔR 1Hepatobiliary between different subjects was sensitive to a number of different factors that are not easily corrected, such as the patientspecific liver volume, renal function and the injected dose in comparison with the blood plasma volume. To minimise the influence from such inter-examination effects, the relative hepatobiliary accumulation of contrast agent (F Hep ) was calculated by dividing ΔR 1Hepatobiliary with ΔR 1Blood&EES obtained from the measurements in the spleen, thus:
The exact value of the volume fraction factors is not very critical in the model, but may be approximated according to the values of a standard human subject using 8 Liver =0.23 and 8 Spleen =0.3 [17] , and therefore:
After inspection of the dynamics of F Hep following the arterial phase measurement, it was proposed that a linear increase in F Hep during the hepatobiliary phases occurred in the subjects. Therefore a least-squares regression analysis was used to obtain the slope (K Hep ) from the following relation:
Here t is the contrast agent exposure time. The major advantage obtained by the introduction of such a procedure (Eq. 11) was that all observations in the time series after the arterial phase could be used to improve the signal-to-noise ratio. In late time phases using Gd-EOB-DTPA, the estimation of F Hep was more sensitive to noise in the Other measures of late hepatobiliary uptake and blood plasma clearance Unprocessed SI measurements from liver and spleen ROIs were used to calculate the quantitative liver-spleen contrast (LSC) ratio, according to the description in Motosugi et al. [7] In the context of SI normalisation being used in the pharmacokinetic model, it is reasonable to attempt normalisation of the liver and spleen SI values to form a modified LSC ratio, here named the normalised liverto-spleen contrast ratio, LSC_N, according to the following expressions:
The splenic blood clearance rate (SBC) for each subject was estimated by least squares fitting of the estimated ΔR 1Spleen to a monoexponential function,
where a is the amplitude scaling factor and t is the time after contrast agent injection.
Statistics
Interval variables were described with mean and standard deviation, and ordinal variables using median and range. K Hep , LSC and LSC_N in each healthy subject for both Gd-EOB-DTPA and Gd-BOPTA were compared using pairwise Pearson correlation and also linear regression anaylses. The group means of K Hep , bilirubin, LSC and LSC_N representing clinical grades 1-3 in the patient group were compared using a one-way ANOVA. As the Levene test showed unequal variances across groups for almost all tested parameters, post-hoc testing was performed according to Games-Howell using BrightStat [18] . Except for the Games-Howell test, statistical calculations were performed in JMP 6.0 (SAS Institute, Cary, NC, USA) or MATLAB R2009a (The MathWorks, Inc. Massachusetts, USA).
Results
Hepatobiliary uptake
Healthy subjects
Mean and standard errors of SI, normalised SI and dose normalised ΔR 1 in the splenic and liver ROIs for all ten healthy subjects using Gd-EOB-DTPA and Gd-BOPTA are shown in Fig. 4 , panels A-C. In panel D the time series of F Hep is shown together with the ratios of F Hep determined using Gd-EOB-DTPA and Gd-BOPTA, respectively. Calculated uptake rates K Hep , LSC and LSC_N ratios and clearance rates are listed in Table 3 . The pairwise correlation between the fitted K Hep for each subject using Gd-EOB-DTPA and Gd-BOPTA was significant (P < 0.05) with r =0.64 (Fig. 5a ). The fitted regression slope was (estimate ±standard error) 7.42± 3.66 and the fitted intercept was 0.14± 0.12. When a constrained intercept (equal to zero) was used in the regression the estimated slope was 11.0 ±1.65. Conversely, no strong correlation was observed between the hepatic uptake of Gd-EOB-DTPA and Gd-BOPTA using LSC_20 (Fig. 5b) .
Patients
Calculated uptake rates K Hep , LSC and LSC_N ratios, bilirubin values, blood clearance rates, Child-Pugh and MELD scores are reported in Table 4 , where diagnoses in clinical grades 1-3 are also listed. In one of the clinical grade 1 patients, it was not possible to obtain the LSC_20/ LSC_N20. The group means of K Hep , LSC_N10 and LSC_N20 of the clinical grades 1-3 were significantly different and pairwise comparisons yielded significant differences between clinical grades 1 and 2, and between 1 and 3, but not between clinical grades 2 and 3 (Table 4) . Also for LSC_10, LSC_20 and bilirubin the group means were significantly different. The Games-Howell test showed significant differences between clinical grades 1 and 3, and between 2 and 3 for both LSC_10 and LSC_20. For bilirubin, there was a significant difference only between clinical grades 1 and 3.
Plasma clearance rate
The plasma clearance rate estimated using SBC was significantly higher using Gd-EOB-DTPA than Gd-BOPTA (P< 0.002; paired Student's t-test) ( Table 3) . Among the patients a significantly lower SBC was observed in the clinical grade 3 group compared with the clinical grade 1 group (Table 4) .
Discussion
Quantitative measurement of the hepatobiliary contrast agent uptake
In this work, a method for the quantification of hepatocytespecific contrast agent kinetics in the human liver was developed based on standard 3D T 1 -weighted GRE images acquired using high-spatial resolution and full liver coverage. The results clearly illustrate that quantitative analysis of the signal response of a T 1 -enhancing contrast agent provides greater insight into the underlying contrast agent kinetics. By estimation of ΔR 1 using well-known physical relationships, a measure of the contrast agent concentration in the tissue was achieved. The method described here, in which the hepatic contrast agent concentration was correlated to the plasma concentration (as observed in the spleen), enables both quantitative measurements and characterisation of the late hepatic uptake. In contrast to the procedure proposed by Motosugi et al., who also used the splenic tissue as reference tissue [7] , the method presented here provides physiologically interpretable values.
The assumption of fixed intrinsic (unenhanced) relaxation values, T 10 , of the tissues is a simplification. The T 10 of and spleen (dotted lines) for Gd-EOB-DTPA (blue lines) and Gd-BOPTA (red lines) from 0 to 40 min, for all ten volunteer subjects. b Normalised SI [S, normalised using the intrinsic, unenhanced SI; Eq. 1]. c Estimated increase in relaxation rate (ΔR 1 ). d F Hep for Gd-EOB-DTPA and Gd-BOPTA and the ratio between these estimates (black dotted line). The curves represent mean value and standard error (SE) for all subjects liver used here was 586 ms, reported by de Bazelaire et al. [14] , with a standard deviation of 39 ms. Thomsen et al. [19] described a larger variation and they reported that the T 1 is prolonged in cirrhosis patients. Van Lom et al. [20] also reported more variation, T 10 =568±59 ms (mean ± SD). The addition of a quantitative T 1 -mapping sequence would provide the means to address interindividual variations as well as intraindividual changes, e.g. due to treatment-induced tissue changes, in order to improve the pharmacokinetic analysis. Furthermore, quantitative imaging methods [21] would probably lead to a more finely detailed analysis with respect to errors in flip angles, coil sensitivity and patient motion.
However, while the pulse sequences used in clinical DCE-MRI of the liver are capable of imaging small anatomical structures with a very large field of view, within the time of a single breath-hold, and are insensitive to fatty infiltration, they are not primarily designed for quantitative imaging. We therefore believe that the quantification methodology presented here may represent an important step forward in clinical DCE-MRI.
Characteristics of the hepatobiliary uptake
The hepatic uptake rate K Hep provided significant separation of patients without hepatobiliary disease from those with hepatobiliary disease, both without and with manifest biliary stasis; there was no significant difference between the two latter groups. Conversely, the serum bilirubin level and the simple liver-to-spleen ratio (LSC) showed a significant difference between the two patient groups with hepatobiliary disease, but no significant separation between these and patients with normal function. We therefore believe that the apparently greater ability of K Hep and the normalised LSC_N ratios to discriminate between clinical grades 1 and 2 is an indication that the K Hep estimate has a test response suitable for early detection of disturbed hepatobiliary function. The similar discrimination capability of LSC_N implies that the signal normalisation procedure is the most important factor for removing patient-specific bias in the functional characterisation.
Contrary to mere normalisation as used here to obtain LSC_N, the process to convert SI to contrast agent concentration values adjusts for the (inherently) non-linear influence of important MRI parameters such as T R , native T 1 and α, for each acquisition. In addition, several image acquisitions in late time phases can be used in calculating Table 3 Hepatobiliary uptake of Gd-EOB-DTPA and Gd-BOPTA in 10 healthy subjects estimated using the liver-to-spleen contrast ratio at 10 and 20 min post-contrast agent injection (LSC_10 and LSC_20), the modified LSC ratio obtained after normalisation using the native liver and spleen ROI signal intensities, (LSC_N10, LSC_N20), and K Hep describing the hepatobiliary specific contrast agent uptake in late time phases. The splenic blood clearance rate (SBC) is also given. A paired t-test showed significant differences between the Gd-EOB-DTPA and the Gd-BOPTA groups for all uptake and clearance parameters The ratio of hepatobiliary uptake of Gd-EOB-DTPA to that of Gd-BOPTA was estimated through a fitted regression slope, which amounted to an uptake rate approximately 11 times higher for Gd-EOB-DTPA, in agreement with pre-clinical studies [3, 22] . In addition, the plasma clearance rate determined from splenic ROI measurements was higher for Gd-EOB-DTPA, which agrees with its shorter plasma halflife compared with Gd-BOPTA [3, 22] .
The lack of accurate non-invasive measures of liver dysfunction was addressed by applying a clinician's grading of the patient hepatobiliary function. A retrospective study by Tajima et al. [23] on differences between patients with chronic liver dysfunction and those with normal liver function has some similarities to our patient study in that the patient records formed the basis of patient grouping. Prospective study designs incorporating for example, liver biopsies and ICG clearance tests, can improve the classification of hepatobiliary dysfunction and provide assessment of possible bias by gender or age. Another limitation is the assumption that the blood and EES compartment of the spleen is similar to that of the liver. This introduces sensitivity to splenic disease into the method. The practical significance of this limitation should also be defined in prospective studies.
Lee et al. [24] found in a study on living liver donors that Gd-EOB-DTPA and Gd-BOPTA are equally useful to characterise vascular and biliary variations, at least from a qualitative point of view. This finding is strengthened by the results from the quantitative evaluation model presented here, that is, the observation that the uptakes of the two contrast agents are correlated. Our interpretation is that the estimated uptake rate of either contrast agent may represent a similar aspect of liver function, possibly indicating a close relationship between the patient-specific characteristics of these contrast agents. From a methodological point of view, the observed correlation and the approximately tenfold ratio between hepatobiliary Gd-EOB-DTPA and Gd-BOPTA uptake rates measured in healthy subjects suggest that the method was able to accurately estimate the hepatobiliary uptake, despite large differences in blood contrast agent concentration kinetics and administered dose. Future studies will be needed to ascertain whether K Hep values may be compared between studies differing in equipment, injection and acquisition protocols, a goal that one can hardly expect to reach with the simpler LSC_N measure. This method enables quantitative assessment of the hepatic uptake of liver specific contrast agents. The clinical relevance of determining the hepatic uptake of Gd-EOB-DTPA and Gd-BOPTA is not yet proved, but the method is suitable as a combined tool for characterisation of regional and global liver function, especially as focal lesions may be characterised within the same examination. Animal investigations have shown promising correlation between hepatobiliary contrast uptake and liver fibrosis [4, 5] . In agreement with the results by Motosugi et al., the observations in this study indicate that hepatobiliary function can be assessed with our method. The possibility to assess regional contrast agent uptake may also be useful for preoperative characterisation and quantification of liver function in patients undergoing hepatic surgery, for example segmental hepatectomy. Since the K Hep estimate is quantitatively derived from local image data, it provides a foundation for various parametric analyses on a segmental or pixel level.
In conclusion, a signal rescaling procedure to correct for the non-linear SI response of T 1 -weighted images acquired using a standard clinical abdominal DCE imaging protocol has been demonstrated. Utilising simple pharmacokinetic modelling, the hepatobiliary uptake of Gd-EOB-DTPA and Gd-BOPTA was shown to correlate well in healthy subjects, and the ratio of the hepatobiliary uptake between the two contrast agents was in agreement with preclinical studies. In addition, it was shown that impaired hepatobiliary function influences the hepatic uptake of Gd-EOB-DTPA.
